View all news

    Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

    04/30/2018
    Download(opens in new window)PDF 161 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com